Overview Dividends

(ARWR) Arrowhead Pharmaceuticals - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US04280A1007

Plozasiran, Olpasiran, Fazirsiran, Zodasiran, Daplusiran

Biotechnology
Market Cap in USD: 5,593m

IPO / Inception: 1993-06-16
Return 12m vs S&P 500: 139%

EPS (Earnings per Share)

EPS CAGR: 14.74%
EPS Trend: -0.9%

Last SUE: 0.23
Qual. Beats: 0

Revenue

Rev. CAGR: -8.21%
Rev. Trend: -28.3%

Last SUE: -0.01
Qual. Beats: 0

Dividends

Currently no dividends paid

Risk via 10d forecast
Volatility	125%
Value at Risk 5%th	185%
Relative Tail Risk	-10.13%

Reward TTM
Sharpe Ratio	1.80
Alpha	187.12
CAGR/Max DD	0.29

Character TTM
Hurst Exponent	0.403
Beta	1.762
Beta Downside	1.807

Drawdowns 3y
Max DD	75.86%
Mean DD	35.79%
Median DD	36.85%

Description: ARWR Arrowhead Pharmaceuticals November 10, 2025

Arrowhead Pharmaceuticals (NASDAQ: ARWR) focuses on RNA-targeted medicines for hard-to-treat diseases. Its late-stage portfolio includes three Phase 3 candidates-Plozasiran (hypertriglyceridemia, dyslipidemia, familial chylomicronemia syndrome), Olpasiran (apo-A reduction) and Fazirsiran (alpha-1 antitrypsin-related liver disease)-plus a suite of Phase 2/1 programs targeting metabolic, hepatic, pulmonary and rare-disease indications. The company leverages a network of collaborations with GlaxoSmithKline, Horizon Therapeutics, Takeda and Amgen to co-develop and commercialize its RNAi platform.

As of the most recent filing, Arrowhead reported a market capitalization of roughly $2.5 billion and cash and equivalents of $300 million, giving it an estimated 12-month runway at current burn rates (~$200 million FY 2023 R&D spend). The biotech sector’s revenue growth is projected at a 10 % CAGR through 2029, driven by expanding demand for gene-silencing therapeutics and favorable reimbursement trends for rare-disease treatments-factors that could amplify ARWR’s upside if its Phase 3 readouts meet primary endpoints.

For a deeper dive into Arrowhead’s valuation metrics and scenario analysis, you might find the research tools on ValueRay worth exploring.

Piotroski VR‑10 (Strict, 0-10) 2.5

Net Income (-148.4m TTM) > 0 and > 6% of Revenue (6% = 35.8m TTM)

FCFTA -0.01 (>2.0%) and ΔFCFTA 58.92pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 126.1% (prev 1798 %; Δ -1672 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.02 (>3.0%) and CFO 21.8m > Net Income -148.4m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 4.87 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (139.0m) change vs 12m ago 11.95% (target <= -2.0% for YES)

Gross Margin 94.78% (prev 11.29%; Δ 83.49pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 52.69% (prev 2.22%; Δ 50.47pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -0.91 (EBITDA TTM -52.5m / Interest Expense TTM 82.3m) >= 6 (WARN >= 3)

Altman Z'' -2.61

(A) 0.54 = (Total Current Assets 946.9m - Total Current Liabilities 194.5m) / Total Assets 1.38b

(B) -1.16 = Retained Earnings (Balance) -1.60b / Total Assets 1.38b

warn (B) unusual magnitude: -1.16 — check mapping/units

(D) -1.86 = Book Value of Equity -1.60b / Total Liabilities 860.8m

Total Rating: -2.61 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 33.11

1. Piotroski 2.50pt

2. FCF Yield -0.33%

3. FCF Margin -2.95%

4. Debt/Equity 1.37

5. Debt/Ebitda 0.33

6. ROIC - WACC (= -22.55)%

7. RoE -41.19%

8. Rev. Trend -28.29%

9. EPS Trend -0.94%

What is the price of ARWR shares?

As of November 27, 2025, the stock is trading at USD 57.71 with a total of 7,064,950 shares traded.
Over the past week, the price has changed by +48.09%, over one month by +46.18%, over three months by +172.47% and over the past year by +174.16%.

Is ARWR a buy, sell or hold?

Arrowhead Pharmaceuticals has received a consensus analysts rating of 4.13. Therefore, it is recommended to buy ARWR.

Strong Buy: 7
Buy: 3
Hold: 5
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the ARWR price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	55.2	-4.4%
Analysts Target Price	55.2	-4.4%
ValueRay Target Price	60.1	4.2%

ARWR Fundamental Data Overview November 25, 2025

Market Cap USD = 5.59b (5.59b USD * 1.0 USD.USD)
P/E Forward = 111.1111
P/S = 9.7605
P/B = 10.7072
P/EG = -1.32
Beta = 1.31
Revenue TTM = 596.6m USD
EBIT TTM = -75.1m USD
EBITDA TTM = -52.5m USD
Long Term Debt = 200.3m USD (from longTermDebt, last quarter)
Short Term Debt = 47.0m USD (from shortTermDebt, last quarter)
Debt = 713.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -17.1m USD (from netDebt column, last quarter)
Enterprise Value = 5.41b USD (5.59b + Debt 713.3m - CCE 900.4m)
Interest Coverage Ratio = -0.91 (Ebit TTM -75.1m / Interest Expense TTM 82.3m)
FCF Yield = -0.33% (FCF TTM -17.6m / Enterprise Value 5.41b)
FCF Margin = -2.95% (FCF TTM -17.6m / Revenue TTM 596.6m)
Net Margin = -24.88% (Net Income TTM -148.4m / Revenue TTM 596.6m)
Gross Margin = 94.78% ((Revenue TTM 596.6m - Cost of Revenue TTM 31.1m) / Revenue TTM)
Gross Margin QoQ = 77.59% (prev 98.88%)
Tobins Q-Ratio = 3.92 (Enterprise Value 5.41b / Total Assets 1.38b)
Interest Expense / Debt = 3.42% (Interest Expense 24.4m / Debt 713.3m)
Taxrate = -1.69% (negative due to tax credits) (2.97m / -175.7m)
NOPAT = -76.3m (EBIT -75.1m * (1 - -1.69%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 4.87 (Total Current Assets 946.9m / Total Current Liabilities 194.5m)
Debt / Equity = 1.37 (Debt 713.3m / totalStockholderEquity, last quarter 519.8m)
Debt / EBITDA = 0.33 (negative EBITDA) (Net Debt -17.1m / EBITDA -52.5m)
Debt / FCF = 0.97 (negative FCF - burning cash) (Net Debt -17.1m / FCF TTM -17.6m)
Total Stockholder Equity = 360.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -10.75% (Net Income -148.4m / Total Assets 1.38b)
RoE = -41.19% (Net Income TTM -148.4m / Total Stockholder Equity 360.3m)
RoCE = -13.39% (EBIT -75.1m / Capital Employed (Equity 360.3m + L.T.Debt 200.3m))
RoIC = -11.06% (negative operating profit) (NOPAT -76.3m / Invested Capital 690.1m)
WACC = 11.49% (E(5.59b)/V(6.31b) * Re(12.51%) + D(713.3m)/V(6.31b) * Rd(3.42%) * (1-Tc(-0.02)))
Discount Rate = 12.51% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 13.77%
Fair Price DCF = unknown (Cash Flow -17.6m)
EPS Correlation: -0.94 | EPS CAGR: 14.74% | SUE: 0.23 | # QB: 0
Revenue Correlation: -28.29 | Revenue CAGR: -8.21% | SUE: -0.01 | # QB: 0

Additional Sources for ARWR Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle